INKT - NASDAQ
MiNK Therapeutics, Inc.
$12.76
+1.4%MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
At a Glance
Live Snapshotinkt
Additional Paid-In Capital
Last Annual Value
143.17M
3-Year CAGR
9%
5-Year CAGR
227%
10-Year CAGR
86%
MiNK Therapeutics, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
MiNK Therapeutics, Inc. NASDAQ:INKT | 143.17M | 7.3% | 5.9% | N/A | |
 Equillium, Inc. NASDAQ:EQ | 244.43M | 5.5% | 6.7% | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 500.21M | 3.2% | 4.3% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 0.00 | N/A | N/A | N/A | |
 BeyondSpring Inc. NASDAQ:BYSI | 375.66M | 0.6% | 0.3% | 23.8% | |
 Precision BioSciences, Inc. NASDAQ:DTIL | 621.39M | 6.8% | 8.7% | N/A | |
 Estrella Immunopharma, Inc. NASDAQ:ESLA | 27.22M | 4.1% | 280.1% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 784.71M | 6.7% | 8.9% | 24.6% | |
 Cue Biopharma, Inc. NASDAQ:CUE | 394.80M | 5.3% | 8.5% | 31.9% | |
 MediciNova, Inc. NASDAQ:MNOV | 0.00 | N/A | N/A | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 290.93M | 6.4% | 7.4% | N/A |
MiNK Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your INKT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.